secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001367644-23-000094
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent gets $120M U.S. government order for smallpox vaccine ACAM2000, plus $60.6M for VIGIV
--------------------------------------------------------------------------------

- ASPR exercises third annual option under 10-year, ~$2B contract; $120M for ACAM2000 doses due by June 30, 2023.
- Separate contract option for VIGIV (smallpox treatment) valued at approximately $60.6M also secured.
- Order follows prior NOIPs for ACAM2000, VIGIV, and BAT; strengthens U.S. Strategic National Stockpile.
- Volume is smaller than prior years but supports Emergent's 2023 financial outlook and domestic manufacturing.
- SVP Paul Williams highlights importance of public-private partnerships in biodefense preparedness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000094/0001367644-23-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000094/ebs-20230526.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer